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group than did the 2 high SAA patients on subcutaneous injections
of their group. We explained in the Subjects and Methods section
how infection and inflammation were excluded and discussed there
physical examination, and determination of the acute-phase
proteins, fibrinogen and haptoglobin. The question raised about
syringe-aggregated insulin can be most simply answered by
referring to the text and to reference 6 cited therein.
Both the references cited by Pickup et al as showing no evidence
of amyloidosis in diabetic animals or in patients differ importantly
from our study. The study by Koivisto et al differed in three
significant ways, which are plainly addressed in the sixth paragraph
of our Discussion. The experiments described by Mauer et al
support, rather than contradict, our findings; the insulin used in
these experiments was rendered non-aggregable by the addition of
the detergent SDS.
Most of Dr Deckert and Dr Lauritzen’s comments reiterate
statements made in our paper (eg, the fourth paragraph of our
Discussion). The original data presented by Deckert and Lauritzen
appear to confirm our observation of increased SAA concentration
in patients receiving insulin. We found a mean level in CSII patients
nearly six times that in normal subjects, and nearly twice that
observed in subcutaneous injection patients. These observations are
not surprising, since any insulins available commercially already
have a significant particulate content (discussed in the first
paragraph of our Introduction, and cited in reference 3).
The only point of disagreement appears to be on the relative levels
of SAA in CSII vs UCT patients. This difference may be more
apparent than real, however, since our data are expressed in
arithmetic means while Deckert and Lauritzen use medians. It
would be interesting to compare data from our two groups
expressed in a similar fashion.
Laboratory of Medical Biochemistry,
Rockefeller University,
New York, NY 10021, USA MICHAEL BROWNLEE
SiR,&mdash;Dr Brownlee and colleagues have demonstrated the
excessive production of amyloid-A in diabetic patients using insulin
pumps. They note that intravenous insulin administration has
produced generalised amyloidosis in animals and that localised
amyloid was found in the tissue of a patient at the site where insulin
was delivered by pump. They conclude that insulin used in pumps
might be modified to limit aggregation. It would seem more logical
to recommend that the use of insulin pumps in the USA be severely
restricted until this and other hazards, potential and real, are further
defined and until any benefits of pumping insulin are established.
Americans love gadgets. Predictably, therefore, the very govern-
mental agencies in the United States that are so conservative in
controlling the availability of new drugs tend to be quite the
opposite when a new mechanical device appears on the scene.
Insulin pumps, for example, are available to any physician in the
USA who wants to equip his patient with the latest of more than a
dozen models&mdash;if and only if that patient can meet the considerable
expenditure necessary to secure a pump and can afford all the
accoutrements necessary for its continuing use.
Tight blood sugar control is the holy grail of American
diabetologists, despite the fact that more objective reviews of the
evidence that tight control delays the ravages of microvascular
disease have concluded that the verdict must be "not proved" .1,2
More to the point are the results of short-term studies of insulin
pumps which show that they do not retard retinopathy ornephropathy3-5 and even that retinopathy may be more likely to
1. Bondy PI, Felig P. Relation of diabetic control to development of vascular complica-
tions. Med Clin North Am 1971; 55: 889-97
2. Siperstein MD. Diabetic microangiopathy and the control of blood glucose. N Engl J
Med 1983; 309: 1577-79.
3. Tamborlane WV, Puklin JE, Bergman M, et al. Long-term improvement of metabolic
control with the insulin pump does not reverse diabetic microangiopathy. Diabetes
Care 1982; 5: 58-64.
4 Puklin AE, Tamborlane WV, Felig P, et al. Influence of long-term insulin infusion
pump treatment of Type I diabetes on diabetic retinopathy. Am Acad Ophthalmol
1982; 89: 735-47.
5. Kroc Collaborative Study Group. Near normal glycemic control does not slow
progression of mild diabetic retinopathy. Diabetes 1983; 32 (suppl 1): 10A (abstr).
progress in patients on pumps than in patients treated
conventionally. 6 
017Although the Centers for Disease Contr have concluded that
the incidence of death in patients using insulin pumps is not
significantly increased (35 deaths out of 3500 users over a short
period), .there does seem to be a large number of patients who die
with pumps in place-deaths which in some cases at least would be
totally unexpected had they been on conventional therapy (bacterial
endocarditis from an infected infusion site, for example). The
greatest threat from pumping insulin is the same as that with other
forms of tight control-namely, life-threatening hypoglycaemia. 8
So Brownlee et al have demonstrated yet another potential hazard
to be added to the long list of those associated with pumping insulin.
Yet they circumvent the issue and conclude by revering the
attainment of tight control. To the man whose only tool is a
hammer, all problems are nails. At the very cornerstone of scientific
medicine lies the dictum that, despite our fond wishes and hopes, we
recommend for our patients only treatment proved to be safe and
proved to be effective. All other therapies must be regarded as
experimental. US clinicians should insist that the insulin pump be
withdrawn from general use and studied intensively in a limited
number of centres, as in the UK.
Division of Endocrinology and Metabolism,
University of California, Irvine,
Orange, California 92668, USA
GRANT GWINUP
ALAN N. ELIAS
CHOLESTEROL LOWERING AND THE RISK OF
CORONARY HEART DISEASE
SIR,-I would like to answer the letters published in your March 3
(p 520) and March 17 (p 633) issues commenting on the Lipid
Research Clinics Trial.’ I .
Dr Cottrell, from the British Nutrition Foundation, writes that
"High plasma low-density lipoprotein cholesterol levels may in
some individuals be an early symptom of atherogenesis" and that
"high LDL-cholesterol levels cannot be considered causal except in
the sense that high levels appear to exacerbate a pre-existing
condition in these individuals". Why then, if cholesterol is not
causal, did treatment prevent coronary events in previously healthy
subjects and to the extent predicted by the level andchange in serum
cholesterol? You might as well argue that cigarette smoking is an
early symptom of lung cancer or that not wearing a seat belt is an
early manifestation of incipient brain damage..
Dr Le Fanu has reservations about the cost-effectiveness of
treatment with cholestyramine, which I share, but he also quotes
some data from the trial on the effectiveness of diet which are
misleading. The 14 100 man-years of cholestyramine treatment,
involving 82 tonnes of cholestyramine, would cost 8 million at
today’s NHS prices. The 8 fatal coronary events prevented would,
as Le Fanu calculates, cost about 1 million each. The equivalent
figure for all definite coronary events would be L240 000. The cost
of cholestyramine would have to change by several orders of
magnitude to make it a best-buy, even if it were desirable on all other
grounds. However, Le Fanu then suggests that dietary
manipulation of the serum cholesterol was ineffective because the
mean cholesterol fell from 279 to 277 mg/dl over 7 years. The figure
of 279 mg/dl was achieved after introduction of the diet, and the
mean cholesterol level in these men before this had been 292 mg/dl.
Also, anyone whose cholesterol fell sharply with diet alone was
eliminated before randomisation-ie, the men whose serum
cholesterol fell from 292 to 279 mg/dl were the comparative non-
responders to diet. The American population shows a modest
increase in cholesterol levels with age so that a few more mg/dl of
presumed benefit might be added for the expected rise over 7 years
6. Lauritzen T, Frost-Larsen K, Larsen HW, et al. Effect of 1 year of near-normal blood
glucose levels on retinopathy in insulin-dependent diabetics. Lancet 1983; i:
200-04.
7. Teutsch SM, Herman WH, Dwyer DM, Lane JM. Mortality among diabetic patients
using continuous subcutaneous insulin-infusion pumps. N Engl J Med 1984; 310:
361-68.
8. Smith LH, Boushey HA, Warnock DG, et al. Hypoglycemia: a pitfall of insulin
therapy. West J Med 1983; 139: 688-95.
1. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary
Prevention Tnal: Results. JAMA 1984; 251: 351-64.
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had no special diet been taken. However, the trial was not designed
as a trial of diet in cholesterol lowering; there is plenty of evidence
that cholesterol levels are culturally determined2 and can be
changed by altering the dietary norm. The problem in changing
cholesterol is in getting individuals to behave radically differently in
their diet from their peers. As an example of the effectiveness of
dietary control, 54 volunteers in North Karelia in Finland were
switched from their traditional atherogenic diet to a southern
European substitute and back again.3 Mean serum cholesterol
levels fell from 263 mg/dl to 201 in men and from 239 mg/dl to 188
in women; a fall occurred in every individual.
Dr Pinckney raises the question of cancer and cholestyramine. In
the trial there were 57 cancer cases in the placebo group (and 15
deaths) versus 57 cancer cases in the cholestyramine group (and 16
deaths). Colon cancer is of some interest from other studies: there
were 6 cases in both groups with no deaths in the placebo group and
2 in the cholestyramine group. For all gastrointestinal cancers
together there were 11 cases (1 death) in the placebo group and 21
cases (not 29) and 8 deaths in the cholestyramine group. These
figures are the basis for Pinckney’s statement that there were "800%
more deaths from cancer" in the cholestyramine group. A rough
estimate of the expected number of gastrointestinal cancers in
14 100 man-years in American men aged 45-54 would be 11 cancers
(and 6 deaths). Since both groups were on a cholesterol-lowering
diet, there does not seem to be good evidence from the trial that
either the diet or the cholestyramine is dangerous, although, of
course, there is no completely untreated control group for
comparison. If cancers at one site are to be singled out, why not
others? One could equally argue that cholestyramine reduced the
frequency of lung cancer (10 to 6), skin cancer (from 10 to 3), and
prostatic cancer (from 11 to 7).
Dr Patel restates the barrage of conflicting advice given to general
practitioners on this subject, typified by the editorials in The Lancet
(Feb 11, p 317) and the British Medical _7ournal 4 the former
seemingly written by a mass interventionist and the latter by a
known advocate of high-risk intervention only. It is the old contrast
between the lumpers and the splitters. The former strategy is more
popular with epidemiologists; the latter is preferred by clinicians,
who like to distinguish patients from others and find the idea of
population-based control frightening. However, the high-risk
salami strategy does pose the problem of where to make the cut.
Even the BMJ’s editorialist, while warning that the trial was a
controlled trial of a drug used only in the top 5% of risk, seemed
ready to extrapolate to the top 20% and to use dietary means first.
While correspondence columns tend to attract controversy, there is
more agreement on the fundamentals of coronary heart disease
prevention than may appear on the surface. S
Cardiovascular Epidemiology Unit,
Nmewells Hospital and Medical School,
Dundee DD19SY HUGH TUNSTALL-PEDOE
SIR,-On the whole, we agree with your assessment of the Lipid
Research Clinics Program (LRCP) statistics. We would add,
however, the following caveats.
(1) For the combined end-point of death definitely due to coronary
heart disease and/or definite myocardial infarction, the results were
significant (p<0 - 05 for a one-sided test) but the difference in event
rates was only 1 - 6% (8’ 6% in the placebo group and 7% in the
cholestyramine group).
(2) There was an excess of 12 deaths in the control group for
definite or suspected CHD mortality; there was an excess of 11 non-
CHD deaths in the treated group. The LRCP considered only the
latter difference to be due to chance alone.
(3) In the design phase a 1% one-sided level of significance was
used for sample size estimation, to allow sufficient power for
2. Keys A. Seven countries: a multivariate analysis of death and coronary heart disease.
Cambridge, Mass: Harvard University Press, 1980.
3. Ehnholm C, Huttunen J, Pietinen P, et al. Effect of diet on serum lipoproteins in a
population with a high risk of coronary heart disease. N Engl J Med 1982; 307:
850-55.
4. Oliver M. Hypercholesterolaemia and coronary heart disease: an answer. Br Med J
1984; 288: 423-24.
5 Goodwin JF, Black D, Ball KP, et al. Prevention of coronary heart disease in the United
Kingdom. Lancet 1982; i: 846-47.
extrapolation to the population as a whole. Yet, the trial data
attained only a 5% one-sided level of significance.
Of even greater significance is the omission from the report of the
LRCP, the National Heart, Lung, and Blood Institute (NHLBI)
press conference on the findings, and from your Feb I editorial, of
a clear distinction between the efficacy of primary intervention
versus secondary. The LRCP was a primary intervention trial-ie,
none of the participants had overt atherosclerotic cardiovascular
disease on entry. Thus, any conclusions drawn from this trial are
applicable only to primary intervention. Although Oliver has cast a
pall over the merits of secondary intervention,l the jury is still out
with respect to the validity of efforts to lower cholesterol late in the
atherosclerotic process. The health care community will have to
wait until about 1990 for a definitive answer for secondary
intervention; that is the scheduled termination date for the Program
on the Surgical Control of the Hyperlipidemias (POSCH) trial.
The POSCH trial is an NHLBI-funded trial that completed
randomisation in July, 1983, with 838 subjects, approximately
evenly randomised to a standard dietary therapy control group and a
partial ileal bypass treated group. Each patient had sustained a
single myocardial infarction, was between the ages of 30 and 64, and
was free of hypertension, diabetes, and obesity on entry. The
qualifying cholesterol concentration for inclusion was 220 mg/dl, or
200-219 mg/dl with an LDL-cholesterol concentration greater than
140 mg/dl. These values are in the mean American range and not the
rather high levels needed for selection into the LRCP trial (>265
mg/dl total cholesterol). Further, the lipid profile effects of the
POSCH surgical intervention far exceed (essentially triple) those
achieved in the LRCP. In POSCH, the extended total cholesterol
reduction (test group minus controls) has been 25% (LRCP 8 - 5%),
the LDL-cholesterol lowering 40% (LRCP 12-6%), the HDL-
cholesterol elevation 8% (LRCP 1 - 6%), and the increase in the
HDL/LDL ratio 80% (LRCP 16%).
We believe that, even though the results of a primary intervention
trial cannot be applied to secondary intervention, the findings of a
secondary trial, if demonstrating an improvement in prognosis with
cholesterol lowering, would logically be transferable to the primary
situation. Therefore, the POSCH trial will not only give a
conclusive answer for secondary intervention but also may well








SIR,-The consensus, following Dr Basil Rifkind’s presentation
of the results of Lipid Research Clinics Coronary Primary
Prevention Trial2,3 to the 24th Annual Conference on Cardio-
vascular Disease Epidemiology of the American Heart Association
here last month, was that there was clear evidence that reducing
very high plasma concentrations of cholesterol and of low density
lipoprotein lowered the incidence of coronary heart disease (CHD).
An earlier cohort study of five year CHD mortality (ICD8
390-358) in 5616 males examined in Paisley, Scotland, showed a
higher absolute risk, relative risk ratio, risk difference, and
population attributable mortality for 377 males under 50 years of
age in the range 6 - 8 to 7 - 5 mmol/1 compared with 2667 males with
less than 6’7 mmol/1 (p=0’07), and with 165 males with baseline
cholesterol levels greater than 7 - 5 mmol/1.4 This observation is but
one of many arising in the study of the various risk factors for CHD
supporting the view that the reduction of multiple small risks
distributed widely over a defined population has the potential of
contributing much more to the reduction of mortality than the
complete and effective treatment of the small number at very high
risk in the same defined population. 5
1. Oliver M. Serum cholesterol: the knave of hearts and the joker. Lancet 1981; ii:
1090-95.
2. The Lipids Research Clinics Coronary Primary Prevention Trial. Results I: Reduction
in incidence of coronary disease. JAMA 1984; 251: 251-64.
3. The Coronary Primary Prevention Trial. Design and implementation. J Chron Dis
1979; 31: 609-31.
4. Hawthorne VM. Diet and coronary heart disease. Br Med J 1977; ii: 187-88.
5. WHO Expert Committee. Prevention of coronary artery disease. WHO Tech Rep Ser
1982, no 678.
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A recent review of changes in risk factors over time in Renfrew,
Scotland, of a cohort of 3000 males and females aged 45 to 64 years,
examined in 1972 and 1977 in the same study, showed a rise in
cholesterol in this interval in all four age and sex groups. This
finding contrasts with a decline in systolic and diastolic blood
pressure and cigarettes consumed per day (the latter except for
younger women). That this should occur while the trend in CHD
mortality in Scotland continued upwards, and when cholesterol
levels were even higher in the Scottish cohort than for those in each
age and sex matched group of the Tecumseh, Michigan, USA,
cohort,6 surely constitutes sufficient grounds for reviewing public
and health professional policies regarding advice to the public on
reducing dietary cholesterol.
Most clinicians and community medicine specialists will endorse
Prof M. F. Oliver’s caveat about not estrapolating too far from a
study of treatment in a group judged to be at the highest risk from
cholesterol to recommendations about changes in diet for
the general population. However, grounds for caution are one
thing, inanition in the present epidemiological situation is another
altogether. It would seem timely to call for a campaign to alert the
Scottish population, particularly in the west if nowhere else, to
their need for dietary change. If that approach seems too
immoderate, then perhaps an immediate start might be made by
bringing to the attention of the agricultural and food industries the
needs of their customers. These industries should be reminded
again of their responsibilities for at least a proportion of present
high CHD mortality and morbidity through failure to do anything
to reduce the cholesterol content and increase the polyunsaturated:
saturated fat ratio of the Scottish diet.
Department of Epidemiology,
School of Public Health,
University of Michigan,
Ann Arbor, Michigan 48109, USA VICTOR M. HAWTHORNE
STREPTOCOCCUS FAECALIS:
GROUP D OR GROUP G?
SIR,-We wish to report on the high incidence of Streptococcus
faecalis strains which apparently possess the Lancefield group G, as
well as the group D antigen. We first observed this cross-reaction in
streptococcal grouping sera about six months ago but, in a current
survey, 17 out of 36 strains (47%) isolated over a three week period
have reacted with both groups D and G antisera. The strains
described have arisen from four separate hospitals in the Salford
district, as well as from outpatient departments and general
practice, making a common source seem highly unlikely. The cross-
reactions can be demonstrated in two widely used commercial
grouping kits (’Streptex’, Wellcome Diagnostics; ’Phadebact’,
Pharmacia Diagnostics) as well as by traditional Lancefield
grouping techniques.
Although most of the strains show equally strong reactions with
both groups D and G antisera, several have demonstrated a signi-
ficantly stfonger reaction with group G. We feel that this could lead
to a misidentification of these strains if Lancefield grouping is used
as the sole criterion for identification, especially since most of the
cross-reacting strains are also strongly &bgr;-haemolytic. This could
have important therapeutic implications because conventional
group G streptococci are typically sensitive to a wide range of
commonly used antimicrobial agents. In contrast, our cross-reacting
Strep faecalis strains, as well as being relatively insensitive to
penicillin appear to be resistant to tetracyclines, macrolides, linco-
samides, sulphoriamides, and trimethoprim. Details of their
antibiotic susceptibility patterns and biochemical characteristics are
to be published elsewhere.
We would be interested to hear from others who have encountered
these strains, to determine their geographical incidence, and also to
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TRAZODONE ASSOCIATED WITH PRIAPISM
SIR,-The new antidepressant drug trazodone (’Desyrel’, Mead-
Johnson ; ’Molipaxin’, Roussel) may have a significant side-effect.
One of my patients (a physician) acquired priapism as a direct result
of the use of trazodone. He required urological surgery and there
may be permanent sequelae. I suggest that until this matter is better
understood we avoid using trazodone in male patients (and,
perhaps, all patients), because of the potential for serious
complications, which seems to be greater than that of many of the
more widely used and accepted antidepressants. On Nov 22, 1983,
Dr Gordon McKinney, of Mead-Johnson Laboratories, told me
that, as of March, 1982, there had been twenty official reports of
priapism linked with trazodone.
Boston Pain Center,
Massachusetts Rehabilitation Hospital,
Boston, Massachusetts 02114, USA GERALD M. ARONOFF
BETA ADRENORECEPTOR ANTAGONISTS IN
ESSENTIAL TREMOR
SIR,-In the treatment of benign, familial, or essential tremor a
beta-adrenoreceptor antagonist is now the drug of first choice, and
propranolol, a non-selective (beta-1 and beta-2) adrenoreceptor
antagonist, having effects on both the peripheral and central
nervous systems, is the most effective. Comparative clinical trialsl,2
suggest peripheral beta-2 adrenoreceptor as the locus of the anti-
tremor effect of these drugs. However; the picture is clouded by
other studies showing benefit from the selective beta-1
adrenoreceptor antagonist metoprolol3-5 and by the apparent
absence of attenuation of essential tremor after intravenous or intra-
arterial propranolol,6 suggesting that a central mechanism is
involved in the therapeutic response to oral propranolol. A Lancet
editorial7 asked for studies with a peripherally acting, selective
beta-2 adrenoreceptor antagonist to evaluate more directly the role
of the beta-2 receptor in the control of essential tremor. We report
the preliminary findings of such a study, double-blind and placebo
controlled, in which the tremolytic effect of a single oral 2 mg dose
of the very hydrophilic (peripherally acting) selective beta-2
adrenoreceptor antagonist LI 32-468 (4-(3-tert-butylamino-2-
hydroxypropoxy)spiro[cyclohexan-1,2-indan)-1-on hydrogen
malonate) was compared with propranolol at a dose (120 mg) known
to be superior to placebo in essential tremor. 
8
Twelve previously untreated patients with essential tremor
received all three treatments in random order with intervals of at
least a week. Tremor of the hands in pronated posture was recorded,
under standardised conditions, by accelerometers.8 The amplitude
of the dominant tremor peak was measured with a spectral analyser
and the root mean square acceleration was computed. Recordings
were made before and 2 h after drug or placebo administration when
drug plasma concentrations were expected to be approaching a peak.
Tremor frequencies ranged from 5 - 7 to 9 - 6 Hz before treatment
and did not change significantly after administration of either of the
drugs or placebo. Pretreatment amplitudes ranged from 5-8 to
102’ 7 x 10-3 3 (g=981 cm/s2). Mean reduction in tremor amplitude
was 9 - 67o after placebo, 42 - 407o (p<0 05) after 2 mg LI 32-468
and 39-4% (p<0 05) after 120 mg propranolol. Significant
decreases in standing tachycardia were observed after adminis-
tration of propranolol (p<0 01), but not after placebo or LI 32-468.
Thus 2 mg LI 32 -468 had no measurable effect on cardiac (beta-1)
receptors.
1. Jefferson D, Jenner P, Marsden CD. Beta-adrenoceptor antagonists in essentialtremor
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